Novo Holdings A/S’s Corvus Pharmaceuticals CRVS Stock Holding History

Novo Holdings A/S’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-847,906	Closed	-$3.02M	–	52
2020 Q4	$3.02M	Sell	847,906 -541,592	-39%	-$2.18M	0.13%	44
2020 Q3	$5.57M	Sell	1,389,498 -1,538,062	-53%	-$6.15M	0.28%	37
2020 Q2	$7.96M	Hold	2,927,560	–	–	0.51%	25
2020 Q1	$6.18M	Hold	2,927,560	–	–	0.41%	18
2019 Q4	$15.9M	Hold	2,927,560	–	–	1.03%	14
2019 Q3	$8.81M	Sell	2,927,560 -1,492,956	-34%	-$6.27M	1.51%	15
2019 Q2	$16.5M	Hold	4,420,516	–	–	2.32%	11
2019 Q1	$17.8M	Hold	4,420,516	–	–	2.63%	9
2018 Q4	$16.2M	Hold	4,420,516	–	–	2.28%	10
2018 Q3	$37.9M	Hold	4,420,516	–	–	3.01%	3
2018 Q2	$48.5M	Hold	4,420,516	–	–	4.88%	3
2018 Q1	$51M	Buy	4,420,516 +1,176,470	+36%	+$11.1M	6.39%	4
2017 Q4	$33.6M	Hold	3,244,046	–	–	4.71%	4
2017 Q3	$51.7M	Hold	3,244,046	–	–	6.73%	4
2017 Q2	$39.3M	Buy	3,244,046 +20,000	+0.6%	+$214K	4.7%	6
2017 Q1	$67M	Hold	3,224,046	–	–	7.13%	5
2016 Q4	$46.1M	Hold	3,224,046	–	–	4.39%	7
2016 Q3	$53M	Hold	3,224,046	–	–	4.71%	7
2016 Q2	$46M	Buy	3,224,046 +70,000	+2%	+$946K	4.83%	6
2016 Q1	$45.7M	Buy	+3,154,046	New	+$45.3M	5.01%	5

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Novo Holdings A/S's CRVS Position: Q1 2021 in Review

Novo Holdings A/S sold out of Corvus Pharmaceuticals (CRVS) in Q1 2021, closing a stake of 847,906 shares — an estimated $3.02M sold.

Novo Holdings A/S first reported a position in CRVS in Q1 2016 and held it in 20 quarters. The position peaked at $67M in Q1 2017. 49 funds tracked by Wall St. Rank hold CRVS as of Q1 2021.

Novo Holdings A/S reported no remaining Corvus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Novo Holdings A/S sold 847,906 Corvus Pharmaceuticals shares in Q1 2021, an estimated $3.02M.
Novo Holdings A/S first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 20 quarters.
Novo Holdings A/S's Corvus Pharmaceuticals position peaked at $67M in Q1 2017.
49 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2021.

Based on Novo Holdings A/S's 13F filing for Q1 2021, filed 17 May 2021.